----item----
version: 1
id: {5CE76ECA-6AAE-4DF5-BB42-339E6BB61A51}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/02/04/Shires dry eye drug lifitegrast granted speedy review
parent: {71B77356-F6BE-4338-8E8E-DDD3D21DC0D9}
name: Shires dry eye drug lifitegrast granted speedy review
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: ee86f4e5-2a94-4136-a3a8-91c01f249af4

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 54

Shire's dry eye drug lifitegrast granted speedy review
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 53

Shires dry eye drug lifitegrast granted speedy review
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1584

<p>The FDA has granted a priority review to Shire's new drug application for lifitegrast, an investigational treatment for dry eye disease in adults, and has set 25 October as the <i>Prescription Drug User Fee Act</i> action date.</p><p>Shares of Shire jumped 4.6%, or $11.36, in mid-afternoon trading on 9 April.</p><p>If approved, lifitegrast has the potential to be the first treatment indicated to address both signs and symptoms of dry eye, a multifactorial disease of the tears and ocular surface, which results in symptoms of discomfort, visual disturbance and tear film instability with potential damage to the ocular surface. </p><p>Dry eye, an often chronic and progressive ocular disease, is one of the most common complaints to eye care professionals and represents a significant unmet need.</p><p>Lifitegrast is a novel small-molecule integrin inhibitor that binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes, and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), which is over-expressed in corneal and conjunctival tissues in dry eye disease. </p><p>LFA-1/ICAM-1 interaction contributes to the formation of immunological synapses resulting in T-cell activation and migration to target tissues, according to Shire.</p><p>The company said its NDA for lifitegrast is supported four trials involving more than 1,800 patients, including a Phase II study, two Phase III efficacy and safety studies and one long-term Phase III safety study.</p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 234

<p>The FDA has granted a priority review to Shire's new drug application for lifitegrast, an investigational treatment for dry eye disease in adults, and has set 25 October as the <i>Prescription Drug User Fee Act</i> action date.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 53

Shires dry eye drug lifitegrast granted speedy review
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150204T174746
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150204T174746
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150204T174746
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028386
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 54

Shire's dry eye drug lifitegrast granted speedy review
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357661
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042327Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

ee86f4e5-2a94-4136-a3a8-91c01f249af4
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042327Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
